Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in the USA / NCT06866236
Starting soon Phase 2/3

Use of New Drug QRX-3 for Prevention and Treatment of Chronic Kidney Disease Progression

NCT06866236 · tracked via the Priya Life Science USA tracker
Sponsor
Ebima Clifford Okundaye
Phase
Phase 2/3
Started
2025-10
Last updated
2025-09-08

Condition(s) studied

Chronic Kidney DiseasesAcute Kidney InjuryKidney Failure

Investigational drug(s) / intervention(s)

QRX-3 →

QRX-3: capsule

Study summary

Chronic kidney disease CKD is estimated to affect nearly over 800 million people globally today (with roughly 125,000 people ending up annually on dialysis in the United States alone. CKD is a contributor to illness and is associated with a diminished quality of life and reduced life expectancy . In this study the investigators are using a novel drug to target improved function of the kidneys.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
No
Inclusion Criteria: * Inclusion criteria * Patient with Chronic kidney disease * Estimated Glomerular function by MDRD of less than 60mls/min * Patients with declining renal function ( as measured by eGFR by MDRD ) * Rate of decline of eGFR over the last one year of less than 20% * Negative Serology markers for CKD etiology * Provider perceived adherence to study follow up Exclusion Criteria: Rapid rate of decline in kidney function of \> 20 % over last one year * Symptomatic renal failure * Presence of any suspected Acute renal failure superimposed * Presence of cast , hematuria, or abnormal urinalysis outside of simple UTI * No known reversible cause of renal decline

Primary outcome measure(s)

  • change in Glomerular filtration rate — 1 year
    change percentage in kidney function level measured with cystatin creatinine glomerular filtration rate

Trial sites (1)

FacilityCityRegionStatus
Neukidney Inc Pasedena Texas

More Ebima Clifford Okundaye trials in the USA

Use of QRX3 for Acute Tubular Necrosis Type of Renal Failure in Hospitalized Patients ( QRX-3 in ARF) Starting soon

Other trials for the same condition

SPYRAL GEMINI Pilot Study Recruiting
Establishment of ProNephro AKI (NGAL) Cut Off Value for Risk Assessment of Moderate to Severe Acute Kidney Injury in Adults Active, not recruiting
Real World Evidence Clinical Utility Study of KidneyIntelX Recruiting
Physiologic Signals and Signatures With the Accuryn Monitoring System - The Accuryn Registry Recruiting
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06866236 on ClinicalTrials.gov ↗ ← All trials in the USA